Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study

BACKGROUND: Although several new drugs have been approved in recent years, pulmonary arterial hypertension (PAH) remains a rapidly progressive disease with a poor prognosis. Ambrisentan, a selective endothelin type A antagonist, has been approved for treatment of PAH. This open label study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Y., Jing, Z. C., Zeng, X. F., Liu, J. M., Yu, Z. X., Zhang, G. C., Li, Y., Wang, Y., Ji, Q. S., Zhu, P., Wu, B. X., Zheng, Y., Wang, P. P., Li, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075402/
https://www.ncbi.nlm.nih.gov/pubmed/27770771
http://dx.doi.org/10.1186/s12872-016-0361-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075402/
https://www.ncbi.nlm.nih.gov/pubmed/27770771
http://dx.doi.org/10.1186/s12872-016-0361-9

Ejemplares similares